Liquidia Corporation
LQDA
$34.35
-1.24%
Liquidia Corporation is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), with its lead commercial product YUTREPIA (treprostinil) inhalation powder and an investigational liposomal treprostinil candidate, L606. The company is differentiated by its proprietary PRINT particle-engineering platform, which enables precise production of uniform drug particles and underpins both its inhaled treprostinil franchise and potential pipeline expansion, positioning it as a niche technology-driven challenger in the inhaled PAH space dominated by United Therapeutics and Insmed. The current investor narrative centers on the commercial ramp of YUTREPIA and whether it can sustain rapid revenue growth against fierce PAH competition, a debate sharpened by the stock's violent late-September collapse despite strong reported financials. Investors are also weighing the durability of the company's newly achieved profitability, its elevated valuation multiples, and the wide dispersion in analyst price targets, all against a backdrop of heavy short interest and elevated volatility.…
LQDA
Liquidia Corporation
$34.35
Related headlines
LQDA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Liquidia Corporation's 12-month outlook, with a consensus price target around $54.38 and implied upside of +58.3% versus the current price.
Average Target
$54.38
0 analysts
Implied Upside
+58.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$33 - $70
Analyst target range
Eight analysts cover LQDA with a consensus recommendation of "buy" and a recommendation mean of 1.75, leaning clearly bullish despite the recent collapse. The average target price is $54.375, implying roughly +58.3% upside from the current $34.35, a gap that reflects either significant analyst conviction in the YUTREPIA ramp or targets that have not yet been revised following the late-September crash. The consensus is bullish on paper, but the magnitude of the implied upside alongside a 49.82% one-month decline suggests the Street is either looking through a transient shock or lagging the price action. The target range is wide, from a low of $33.00 (essentially at the current price, implying no upside) to a high of $70.00 (roughly +104% upside), a spread of more than 2x that signals high uncertainty rather than strong conviction. The high target likely assumes sustained YUTREPIA share gains, continued margin expansion, and multiple re-rating toward the pre-crash $70-plus levels, while the low target of $33.00 prices in competitive pressure from United Therapeutics and Insmed, margin compression, or a durable de-rating. Institutional ratings data is stale, with the most recent actions dated August 2024 and showing a uniform wall of Buy/Strong Buy ratings from firms including HC Wainwright, Needham, BTIG, B of A Securities, and Raymond James, so there is no recent upgrade/downgrade signal to confirm or contradict the current consensus; the combination of stale ratings, a wide target spread, and a 5.68 short ratio implies elevated volatility and meaningful two-way risk around upcoming catalysts.
Bulls vs Bears: LQDA Investment Factors
The evidence is genuinely two-sided, but the bear case currently has the stronger near-term grip because the 57% single-day gap on 2026-09-30 represents a discrete, unresolved shock that no fundamental metric can offset until its cause is clarified. The bull case rests on hard numbers — revenue up from $3.12M to $171.68M in five quarters, 93.27% gross margins, 49.81% operating margins, and $69.01M of Q2 free cash flow — that describe a company executing a rare and profitable commercial launch. The bear case rests on equally hard numbers — a 71.54% drawdown, -49.82% one-month return, 4.42 debt-to-equity, and total dependence on a single product facing UTHR and INSM. The single most important tension is whether the late-September collapse reflects a transient, misunderstood event (in which case the $54.375 average target and 15.71x forward PE make this deeply undervalued) or a durable impairment of the YUTREPIA growth trajectory (in which case the $33.00 low target is the ceiling, not the floor). Until that question is answered by disclosure or the next earnings report, the risk/reward is asymmetric but the direction of the asymmetry is unknown.
Bullish
- Revenue inflected from $3M to $172M: Quarterly revenue exploded from $3.12M in Q1 2025 to $171.68M in Q2 2026, a roughly 55x increase in five quarters, with Q2 2026 up 18.43% year over year. The sequential step-ups ($54.34M → $92.02M → $132.87M → $171.68M) show YUTREPIA is a genuine commercial ramp, not a one-off launch spike.
- Profitability flipped decisively positive: Q2 2026 delivered $74.72M net income (43.52% net margin) and $85.52M operating income (49.81% operating margin), versus a $41.58M net loss in Q2 2025. Gross margin climbed from 85.38% to 93.27% over the same period, showing operating leverage as volume scales.
- Analyst targets imply 58% upside: Eight analysts carry a consensus 'buy' with a 1.75 recommendation mean and an average target of $54.375, roughly +58.3% from the $34.35 price. Even the low target of $33.00 sits essentially at the current price, meaning the Street's downside case is already priced in.
- Cash generation and balance sheet improving: Q2 2026 free cash flow was $69.01M on $80.24M operating cash flow, and trailing FCF reached $60.51M, flipping from Q1 2026's -$40.02M burn. Cash of $287.69M plus a 1.40 current ratio provides runway while the franchise scales.
Bearish
- 57% one-day collapse signals major shock: The stock gapped from $70.69 on 2026-09-29 to $30.26 on 2026-09-30, a roughly 57% single-session decline that almost certainly reflects an adverse catalyst (competitive, legal, or guidance-related). A move of that magnitude typically signals a structural change in the thesis, not a sentiment wobble.
- Momentum and relative strength broken: LQDA is down 49.82% over one month and 57.03% over three months versus SPY's +1.22% and +2.69%, producing relative strength of -51.04 and -59.72. The 71.54% max drawdown and price at only ~17% of its 52-week range confirm a falling-knife technical setup.
- Single-product concentration risk: Product revenue of $170.38M versus $1.30M service revenue means YUTREPIA is effectively the entire business, and it competes directly with United Therapeutics and Insmed in PAH. Any share loss, pricing pressure, or reimbursement setback hits 100% of the revenue base.
- Growth decelerating sequentially: Q1-to-Q2 2026 sequential growth of ~29% is strong but well below the near-doubling seen between Q3 and Q4 2025. The market is repricing durability of the ramp, and the 18.43% YoY figure is flattered by a tiny prior-year base rather than reflecting a mature growth rate.
LQDA Technical Analysis
LQDA is in a structurally damaged but partially recovering trend: the stock is up 48.19% over the past year yet sits only about 17% above its 52-week low of $21.94 and roughly 63% below its 52-week high of $93.61, placing it near the bottom of its 52-week range (approximately 17.4% of the range). That positioning reflects a momentum collapse rather than a value base, with the current price of $34.35 having surrendered most of the gains from a powerful first-half advance that peaked near $91 in early August. The 71.54% maximum drawdown underscores how severely the trend reversed, and the stock's location near the lower quartile of its range means it is a falling-knife setup until a durable base forms. Recent momentum is decisively negative and sharply diverging from the longer-term positive 1-year return: the stock is down 49.82% over the past month and 57.03% over three months, versus a 1-year gain of 48.19%, a classic trend-reversal signal rather than a routine pullback. Relative strength confirms the underperformance, with a 1-month relative strength of -51.04 and a 3-month figure of -59.72 against SPY, while the 1-year relative strength remains +32.66, highlighting how concentrated the damage has been in the recent window. The most striking feature is the single-session gap from $70.69 on 2026-09-29 to $30.26 on 2026-09-30, a roughly 57% one-day decline that likely reflects a major adverse catalyst; the subsequent rebound from a $25.91 low on 2026-10-06 to $34.35 represents a partial recovery of about 33% off that trough. Key technical levels are the $21.94 52-week low as the critical support floor and the $93.61 52-week high as distant resistance, with intermediate resistance around the $70 area where the gap originated; a breakout above that gap zone would signal genuine repair, while a breakdown below $25.91 would confirm the downtrend. The beta of 0.61 suggests lower market-correlated volatility than SPY, but that statistic is misleading here given the stock's idiosyncratic, event-driven swings and a short ratio of 5.68, which implies roughly 5.7 days of average volume to cover shorts and raises the risk of sharp squeeze-driven rallies alongside continued downside pressure.
Beta
0.61
0.61x market volatility
Max Drawdown
-71.5%
Largest decline past year
52-Week Range
$22-$94
Price range past year
Annual Return
+48.2%
Cumulative gain past year
| Period | LQDA Return | S&P 500 |
|---|---|---|
| 1m | -49.8% | +0.2% |
| 3m | -57.0% | +2.9% |
| 6m | -13.0% | +8.4% |
| 1y | +48.2% | +14.9% |
| ytd | +9.4% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LQDA Fundamental Analysis
Revenue is inflecting dramatically: Q2 2026 revenue reached $171.68 million, up 18.43% year over year, and the multi-quarter trajectory shows explosive acceleration from $3.12 million in Q1 2025 and $8.84 million in Q2 2025 to $54.34 million in Q3 2025, $92.02 million in Q4 2025, $132.87 million in Q1 2026, and $171.68 million in Q2 2026. Product revenue of $170.38 million versus just $1.30 million in service revenue confirms that the YUTREPIA commercial launch is essentially the entire growth engine, making the investment case highly concentrated on a single franchise facing competition from United Therapeutics and Insmed. The sequential growth from Q1 to Q2 2026 was about 29%, still strong but decelerating from the near-sequential doubling seen in late 2025, which is the key debate for whether the ramp can sustain its pace. Profitability has swung decisively positive: Q2 2026 net income was $74.72 million with a 43.52% net margin, operating income of $85.52 million (49.81% operating margin), and a gross margin of 93.27%, up from a Q2 2025 net loss of $41.58 million and a negative 470.5% net margin. The margin progression is remarkable, with gross margin rising from 85.38% in Q2 2025 to 90.86% in Q1 2026 and 93.27% in Q2 2026, and operating margin improving from -424.4% to nearly 50%, though the trailing net margin of -43.53% and trailing EPS of -$0.023 reflect that the company only recently crossed into profitability. Balance-sheet and cash-flow health is improving but still leveraged: debt-to-equity stands at 4.42, the current ratio is 1.40, and cash was $287.69 million at the end of Q2 2026, while trailing free cash flow was $60.51 million and Q2 2026 free cash flow was $69.01 million on operating cash flow of $80.24 million. The Q1 2026 cash burn of -$40.02 million free cash flow shows the business is not yet consistently cash-generative, and ROE of -154.03% alongside a price-to-free-cash-flow ratio of -83.17 signals that reported profitability is recent and fragile relative to the capital structure.
Quarterly Revenue
$171679000.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
93.3%
Latest Quarter
Free Cash Flow
$60512000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LQDA Overvalued?
Because trailing net income is negative (EPS of -$0.023, trailing PE of -43.11), the PE ratio is not a valid primary metric, so the PS ratio of 18.75x is the appropriate anchor, supplemented by the forward PE of 15.71x and EV/Sales of 6.68x. The gap between the negative trailing PE and the positive 15.71x forward PE implies the market expects a sharp earnings inflection, consistent with consensus estimated EPS of $4.03 and estimated revenue of $1.05 billion, though the EV/EBITDA of -68.84x remains distorted by trailing losses. Peer comparison is constrained by the absence of a supplied industry-average multiple, but the 18.75x PS and 66.33x price-to-book are rich for a commercial-stage biopharma and imply the market is pricing substantial continued growth; the 6.68x EV/Sales is more moderate and suggests the equity multiple is inflated by the capital structure. Historical context shows the PS ratio has compressed dramatically from 41.28x in Q2 2026 and 32.65x in Q4 2025 to 18.75x now, reflecting both the price collapse and the revenue surge, while the price-to-book of 66.33x is near the high end of its own history versus 36.32x in Q2 2026 and 30.59x in Q1 2026. The PEG ratio of 0.83 is the one metric suggesting relative value if growth estimates hold, but the combination of a still-elevated PS multiple and a stock down roughly 57% in three months indicates the market is repricing growth durability rather than offering a clear value opportunity.
PE
-43.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-68.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risk is dominated by concentration and leverage. YUTREPIA generated $170.38M of $171.68M in Q2 2026 revenue, so a single product carries essentially all commercial risk against United Therapeutics and Insmed. Debt-to-equity of 4.42 with $6.30M of quarterly interest expense consumes cash that would otherwise fund the launch, and while Q2 2026 FCF was +$69.01M, Q1 2026 was -$40.02M, showing the cash profile is not yet reliable. Trailing EPS of -$0.023 and ROE of -154.03% confirm that the profitability pivot is only one to two quarters old, and the 93.27% gross margin leaves little room for manufacturing or pricing slippage to be absorbed.
Market and competitive risk centers on valuation compression and event sensitivity. At 18.75x PS and 66.33x price-to-book, LQDA trades at a premium that assumes continued hyper-growth; the PS has already compressed from 41.28x in Q2 2026, and further compression toward the 6.68x EV/Sales level would imply substantial downside. The beta of 0.61 understates true risk because the stock's volatility is idiosyncratic and event-driven, as the 57% one-day gap demonstrates, and the 5.68 short ratio means both squeeze rallies and forced selling are plausible. Zacks has explicitly flagged that intense competition from UTHR and INSM could limit long-term YUTREPIA growth, and with analyst ratings stale since August 2024, there is no fresh Street validation to cushion a negative surprise.
Worst-case scenario: the late-September catalyst proves to be a durable competitive or regulatory impairment, YUTREPIA sequential growth stalls below 10%, and the market re-rates the stock toward the $33.00 low analyst target and then the $21.94 52-week low. From $34.35, that is roughly -4% to the low target and -36% to the 52-week low, and the 71.54% max drawdown shows a deeper retracement toward the mid-$20s is entirely within historical behavior. A breakdown below the $25.91 rebound low of 2026-10-06 would technically confirm the downtrend and could accelerate selling given the heavy short base.